

RECEIVED

164.6

AUG 0 1 2001

TECH CENTER 1600/2900 Atty. Dkt. No. 032026-0460

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Brandt et al.

Title:

PHARMACOLOGICALLY ACTIVE

ANTIVIRAL PEPTIDES AND METHODS

OF THEIR USE

Appl. No.:

09/777,560


Filing Date:

2/06/2001

Examiner:

Art Unit:

1646



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 and presented below is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 C.F.R. §§1.97 and 1.98.

U.S. PATENT DOCUMENTS

DOCUMENT NUMBER	<u>DATE</u>	<u>NAME</u>
5,104,854	4/14/92	Schlesinger et al.
5,182,265	1/26/93	Bruzzese et al.
5,260,420	11/9/93	Burnouf-Radosevich et al.
5,380,727	1/10/95	Déziel <i>et al.</i>
5,645,849	7/8/97	Pruss et al.
5,700,780	12/23/97	Beaulieu <i>et al.</i>

OTHER DOCUMENTS

- G. Wagner and J. Oehlke, "Mercaptopurin-Protein-Azokonjugate," Pharmazie 32 157-162, 1977.
- R. V. Srinivas *et al.*, "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs," <u>Virology 176</u>, pp. 48-57, 1990.
- S. K. Srinivas *et al.*, "Membrane Interactions of Synthetic Peptides Corresponding to Amphipathic Helical Segments of the Human Immunodeficiency Virus Type-1 Envelope Glycoprotein," <u>J. Biol. Chem.</u> 267(10), pp. 7121-7127, April 1992.
- C. Wild *et al.*, "A Synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication: Correlation Between Solution Structure and Viral Inhibition," <u>Proc. Nat'l. Acad. Sci. USA 89</u>, pp. 10537-10541, November 1992.
- D. Derossi *et al.*, "The Third Helix of the Antennapedia Homeodomain Translocates Through Biological Membranes," <u>The Journal of Biological Chemistry 269</u>(14), pp. 10444-10450, April 1994.
- C. Wild *et al.*, "Peptides Corresponding to a Predictive α-Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection," <u>Proc. Nat'l. Acad. Sci. USA</u> 91, pp. 9770-9774, October 1994.
- C. Wild *et al.*, "Propensity for a Leucine Zipper-Like Domain of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates with a Role in Virus-Induced Fusion Rather than Assembly of the Glycoprotein Complex," <u>Proc. Nat'l. Acad. Sci. USA 91</u>, pp. 12676-12680, December 1994.
- J. Oehlke *et al.*, "Utilization of Endothelial Cell Monolayers of Low Tightness for Estimation of Transcellular Transport Characteristics of Hydrophilic Compounds," <u>Euro. J. Pharm. 2</u>, pp. 365-372, 1994.
- Y-Z. Lin *et al.*, "Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-Permeable Motif and Nuclear Localization Sequence,," <u>The Journal of Biological Chemistry 270(24)</u>, pp. 14255-14258, June 1995.
- J. Brugidou *et al.*, "The *Retro Inverso* Form of a Homeobox-Derived Short Peptide is Rapidly Internalized by Cultured Neurones: A New Basis for an Efficient Intracellular Delivery System," <u>Biochemical and Biophysical Research Communications 214(2)</u>, pp. 685-693, September 1995.
- D. Derossi, "Antennapedia Homeodomain Third Helix as a Peptide and Oligonucleotide Vector," Restorative Neurology and Neuroscience 8, pp. 17-18, 1995.
- S. Rothemund *et al.*, "Recognition of α -Helical Peptide Structures Using High-Performance Liquid Chromatographic Retention Data for D-Amino Acid Analogues: Influence of Peptide Amphipathicity and of a Stationary Phase Hydrophobicity," <u>Journal of Chromatography A 689</u>, pp. 219-226, 1995.
- C. Brandt *et al.*, "Evaluation of a Peptidomimetic Ribonucleotide Reductase Inhibitor with a Murine Model of Herpes Simplex Virus Type 1 Ocular Disease," <u>Antimicrobial Agents and Chemotherapy 40(5)</u>, pp. 1078-1084, May 1996.
- D. Derossi *et al.*, "Cell Internalization of the Third Helix of the Antennapedia Homeodomain is Receptor-Independent," <u>The Journal of Biological Chemistry 271</u>(30), pp. 18188-18193, July 1996.
- E. Krause *et al.*, "Conformation of a Water-Soluble β-Sheet Model Peptide," <u>Int. J. Peptide Protein</u> Res. 48, pp. 559-568, 1996.

- J. Oehlke *et al.*, "Nonendocytic, Amphipathicity Dependent Cellular Uptake of Helical Model Peptides," <u>Protein and Peptide Letters 3(6)</u>, pp. 393-398, 1996.
- Q. Yao and R. W. Compans, "Peptides Corresponding to the Heptad Repeat Sequence of Human Parainfluenza Virus Fusion Protein are Potent Inhibitors of Virus Infection, Virology 223, pp. 103-112, 1996.
- G. Elliott and P. O'Hare, "Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein," Cell 88, pp. 223-233, January 1997.
- C. Yang and R. W. Compans, "Analysis of the Murine Leukemia Virus R Peptide: Delineation of the Molecular Determinants Which are Important for Its Fusion Inhibition Activity, <u>Journal of Virology 71(11)</u>, pp. 8490-8496, November 1997.
- J. Oehlke *et al.*, "Extensive Cellular Uptake into Endothelial Cells of an Amphipathic β-Sheet Forming Peptide," Federation of European Biochemical Societies Letter 415, 196-199, 1997.
- L. T. Rimsky *et al.*, "Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides," <u>Journal of Virology 72(2)</u>, pp. 986-993, February 1998.
- M. Rojas *et al.*, "Genetic Engineering of Proteins with Cell Membrane Permeability," <u>Nature Biotechnology 16</u>, pp. 370-375, April 1998.
- A. Phelan *et al.*, "Intercellular Delivery of Functional p53 by the Herpesvirus Protein VP22," <u>Nature Biotechnology 16</u>, pp. 440-443, May 1998.
- S. Y. Hong *et al.*, "Identification and Characterization of Novel Antimicrobial Decapeptides Generated by Combinatorial Chemistry," <u>Antimicrobial Agents and Chemotherapy 42(10)</u>, pp. 2534-2541, October 1998.
- J. M. Kilby *et al.*, "Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry," <u>Nature Medicine 4(11)</u>, pp. 1302-1307, November 1998.
- G. Aldrian-Herrada e al., "A Peptide Nucleic Acid (PNA) is More Rapidly Internalized in Cultured Neurons when Coupled to a *retro-inverso* Delivery Peptide. The Antisense Activity Depresses the Target mRNA and Protein in Magnocellular Oxytocin Neurons," <u>Nucleic Acids Research 26</u>(21), pp. 4910-4916, 1998.
- B. Böttcher *et al.*, "Peptides that Block Hepatitis B Virus Assembly: Analysis by Cryomicroscopy, Mutagenesis and Transfection," The EMBO Journal 17(23), pp. 6839-6845, 1998.
- C. Du *et al.*, "Conformational and Topological Requirements of Cell-Permeable Peptide Function," J. Peptide Res. 51, pp. 235-243, 1998.

REMARKS

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in

37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

The listed document is being submitted in compliance with 37 C.F.R. §1.97(b). Therefore, Applicants believe no fee is required for this filing. However, the Commissioner is authorized to charge any fee due for this submission to Deposit Account No. 06-1447. For the purpose of charging said deposit account, a duplicate copy of this paper is enclosed.

Applicants respectfully request that the listed document be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date July 25, 2001

FOLEY & LARDNER 150 East Gilman Street P. O. Box 1497 Madison, Wisconsin 53701-1497 Telephone: (608) 258-4272

Facsimile:

(608) 258-4258

Mark A. Kassel Attorney for Applicant Registration No. 38,200

Page 1 of 2

Form PTO-14	49	U.S. DEPARTME	NT OF COMMERC	CE	ATTY. DOCKET NO.		SERIAL NO		·
(MODIFIED)	IFIED) PATENT AND TRADEMARK OFFICE		032026-0460		09/777,560				
APPLICANT					APPLICANT				
INFO	ORMATI	ON DISCLOSURE	CITATION P E		\	Brandt e	t al.		
			10	٩	LING DATE		GROUP AR	T UNIT	
	(Use se	everal sheets if nece	ssary JUL 3 0	2001	2/06/2001				
			JJ.S. PA	TEN	OCUMENTS				
EVANUED		DOCUMENT	A TAN	ADE			CLID	FILING	DATE
EXAMINER INITIAL	REF	NUMBER	DATE		NAME	CLASS	SUB- CLASS	IF APPRO	
		5,104,854	4/14/92	Schl	esinger et al.		REC	CEN	/ED
		5,182,265	1/26/93	Bruz	zese et al.) <u></u>	
		5,260,420	11/9/93	Burn	ouf-Radosevich <i>et al.</i>		AU(0 1 20	001
		5,380,727	1/10/95	Dézi	el et al.				
		5,645,849	7/8/97	Prus	s et al.		TECH CEN	11EH 160	0/2900
		5,700,780	12/23/97	Beau	ulieu <i>et al</i> .				
							<u> </u>		
			FOREIGN I	PAT	ENT DOCUMENTS				
• •	REF	DOCUMENT	DATE		COUNTRY	CLASS	SUB-	TRANS	
	KLI	NUMBER	<i>5</i> /(12				CLASS	YES	NO
		OTHER DOCU	MENTS (Includii	ng A	uthor, Title, Date, Perti	nent Pages,	Etc.)		
					ein-Azokonjugate," Pharma				
		pp. 48-57, 1990.	_		oprotein A-I and Its Syntheti				
		Human Immunodefici	ency Virus Type-1 E	Envelo	Synthetic Peptides Correspond Glycoprotein," J. Biol. Cl	<u>nem. 267</u> (10), p	p. 7121-7127,	April 1992.	
					Human Immunodeficiency V <u>1. Sci. USA 89</u> , pp. 10537-10			etween Sol	ution
					napedia Homeodomain Tran 1444-10450, April 1994.	slocates Throu	gh Biological M	lembranes,	" <u>The</u>
		C. Wild et al., "Peptid Potent Inhibitors of V	es Corresponding to irus Infection," Proc.	a Pro Natil	edictive α-Helical Domain of . Acad. Sci. USA 91, pp. 977	Human Immur 0-9774, Octob	odeficiency Vi er 1994.	rus Type 1	gp41 are
		C. Wild et al., "Proper Oligomers Correlates Acad. Sci. USA 91, p	with a Role in Virus	-Indu	Like Domain of Human Immoded Fusion Rather than Asset 1994.	unodeficiency embly of the Gl	Virus Type 1 g ycoprotein Cor	p41 to Form nplex," <u>Proc</u>	n c. Nat'l.
					Monolayers of Low Tightnes		of Transcellul	ar Transpo	rt
					ion of Transcription Factor N ization Sequence,," <u>The Jou</u>				
			sis for an Efficient In	ntrace	a Homeobox-Derived Short I Ilular Delivery System," <u>Bioc</u> ber 1995.				d
		D. Derossi, "Antenna Neuroscience 8, pp.		Thire	d Helix as a Peptide and Olig	gonucleotide V	ector," Restora	tive Neurolo	ogy and
S. Rothemund et al., "Recognition of α-Helical Peptide Structures Using High-Performance Liquid Chromatographic Retention Data for D-Amino Acid Analogues: Influence of Peptide Amphipathicity and of a Stationary Phase Hydrophobicity," Journal of Chromatography A 689, pp. 219-226, 1995.					hobicity,"				

Page 2	? OT 2
--------	--------

•		Page 2 of 2:
•		C. Brandt et al., "Evaluation of a Peptidomimetic Ribonucleotide Reductase Inhibitor with a Murine Model of Herpes Simplex Virus Type 1 Ocular Disease," Antimicrobial Agents and Chemotherapy 40(5), pp. 1078-1084, May 1996.
		D. Derossi <i>et al.</i> , "Cell Internalization of the Third Helix of the Antennapedia Homeodomain is Receptor-Independent," <u>The Journal of Biological Chemistry 271</u> (30), pp. 18188-18193, July 1996.
		E. Krause <i>et al.</i> , "Conformation of a Water-Soluble β-Sheet Model Peptide," Int. J. Peptide Protein Res. 48, pp. 559-568, 1996.
61	- VC.	J. Oehlke et al., "Nonendocytic, Amphipathicity Dependent Cellular Uptake of Helical Model Peptides," <u>Protein and Peptide</u> <u>Letters 3</u> (6), pp. 393-398, 1996.
JUL 3 D	2001	Q. Yao and R. W. Compans, "Peptides Corresponding to the Heptad Repeat Sequence of Human Parainfluenza Virus Fusion Protein are Potent Inhibitors of Virus Infection, <u>Virology 223</u> , pp. 103-112, 1996.
CALENTA T	a Coulet	G. Elliott and P. O'Hare, "Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein," Cell 88, pp. 223 233, January 1997.
-		C. Yang and R. W. Compans, "Analysis of the Murine Leukemia Virus R Peptide: Delineation of the Molecular Determinants Which are Important for Its Fusion Inhibition Activity, <u>Journal of Virology 71</u> (11), pp. 8490-8496, November 1997.
		J. Oehlke <i>et al.</i> , "Extensive Cellular Uptake into Endothelial Cells of an Amphipathic β-Sheet Forming Peptide," Federation European Biochemical Societies Letter 415, 196-199, 1997.
		L. T. Rimsky et al., "Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides," <u>Journal of Virology 72(2)</u> , pp. 986-993, February 1998.
		M. Rojas et al., "Genetic Engineering of Proteins with Cell Membrane Permeability," Nature Biotechnology 16, pp. 370-375, April 1998.
	_	A. Phelan et al., "Intercellular Delivery of Functional p53 by the Herpesvirus Protein VP22," Nature Biotechnology 16, pp. 440-443, May 1998.
		S. Y. Hong <i>et al.</i> , "Identification and Characterization of Novel Antimicrobial Decapeptides Generated by Combinatorial Chemistry," <u>Antimicrobial Agents and Chemotherapy 42</u> (10), pp. 2534-2541, October 1998.
		J. M. Kilby et al., "Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry," Nature Medicine 4(11), pp. 1302-1307, November 1998.
		G. Aldrian-Herrada e al., "A Peptide Nucleic Acid (PNA) is More Rapidly Internalized in Cultured Neurons when Coupled to retro-inverso Delivery Peptide. The Antisense Activity Depresses the Target mRNA and Protein in Magnocellular Oxytocin Neurons," Nucleic Acids Research 26(21), pp. 4910-4916, 1998.
		B. Böttcher et al., "Peptides that Block Hepatitis B Virus Assembly: Analysis by Cryomicroscopy, Mutagenesis and Transfection," The EMBO Journal 17(23), pp. 6839-6845, 1998.
		C. Du et al., "Conformational and Topological Requirements of Cell-Permeable Peptide Function," J. Peptide Res. 51, pp. 235-243, 1998.
		RECEIVE
(AMINER		DATE CONSIDERED AUG 0 1 2001
		TECH CENTER 1600, 2

line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.